药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02268 药明合联

已收盘 07-25 16:08:27

14.360

+0.120

+0.84%

最高14.580	最低14.080	成交量86.22万
今开14.240	昨收14.240	日振幅3.51%
总市值172.06亿	流通市值172.06亿	总股本11.98亿
成交额1,243万	换手率0.07%	流通股本11.98亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02268","market":"HK","secType":"STK","nameCN":"药明合联","latestPrice":14.36,"timestamp":1721894907027,"preClose":14.24,"halted":0,"volume":862182,"delay":0,"floatShares":1198215456,"shares":1198215456,"eps":0.2999028,"marketStatus":"已收盘","marketStatusCode":5,"change":0.12,"latestTime":"07-25 16:08:27","open":14.24,"high":14.58,"low":14.08,"amount":12433594,"amplitude":0.035112,"askPrice":14.36,"askSize":1000,"bidPrice":14.28,"bidSize":2500,"shortable":3,"etf":0,"ttmEps":0.28133166829268297,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721957400000},"adr":0,"listingDate":1700150400000,"adjPreClose":14.24,"openAndCloseTimeList":[[1721871000000,1721880000000],[1721883600000,1721894400000]],"volumeRatio":0.760813,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02268","defaultTab":"news","newsList":[{"id":"2453404355","title":"《大行》野村降药明合联(02268.HK)目标价至28.91元  反映市场状况波动和地缘政治不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2453404355","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453404355?lang=zh_cn&edition=full","pubTime":"2024-07-24 10:48","pubTimestamp":1721789280,"startTime":"0","endTime":"0","summary":"野村发表报告指出，在国内外对抗体偶联药物模式的强劲需求下，预期药明合联上半年收入及盈利实现强劲增长，料按年升44.3%与45.3%，收入高达14.3亿元人民币。该行维持对药明合联的“买入”评级，目标价由32.52元下调至28.91元，反映市场状况波动和地缘政治不确定。沽空资料截至 2024-07-23 16:25。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20231117104105862_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20231117104105862_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1365849/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02268"],"gpt_icon":0},{"id":"2452088498","title":"南向资金7月18日净卖出药明合联90.21万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2452088498","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452088498?lang=zh_cn&edition=full","pubTime":"2024-07-19 09:31","pubTimestamp":1721352696,"startTime":"0","endTime":"0","summary":"7月18日，南向资金减持药明合联90.21万股连续3日减持。截止当日收盘，港股通共持有药明合联5680.91万股，占流通股4.73%。港股通减持金额前五个股分别为香港交易所、中国神华、中国宏桥、理想汽车-W、东岳集团。药明合联近5个交易日下跌6.88%，港股通累计减持140.44万股；近20个交易日下跌14.86%，港股通累计减持46.19万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071909425895d9ab61&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071909425895d9ab61&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999014674.SGD","BK1141","02268"],"gpt_icon":0},{"id":"2452997774","title":"药明合联(02268)上涨5.12%，报15.18元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452997774","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452997774?lang=zh_cn&edition=full","pubTime":"2024-07-17 10:46","pubTimestamp":1721184383,"startTime":"0","endTime":"0","summary":"7月17日，药明合联(02268)盘中上涨5.12%，截至10:46，报15.18元/股，成交1534.98万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2023年年报，药明合联营业总收入21.24亿元、净利润2.84亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/17104641612969.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SG9999014674.SGD","BK1141","02268"],"gpt_icon":0},{"id":"2451692015","title":"药明合联(02268)下跌5.19%，报15.34元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2451692015","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451692015?lang=zh_cn&edition=full","pubTime":"2024-07-15 15:25","pubTimestamp":1721028317,"startTime":"0","endTime":"0","summary":"7月15日，药明合联(02268)盘中下跌5.19%，截至15:25，报15.34元/股，成交2466.38万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2023年年报，药明合联营业总收入21.24亿元、净利润2.84亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/15152541569336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02268","BK1141","SG9999014674.SGD"],"gpt_icon":0},{"id":"2450120304","title":"药明合联(02268.HK)：已批准向211名承授人授出449.69万股受限制股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2450120304","media":"格隆汇资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450120304?lang=zh_cn&edition=full","pubTime":"2024-07-12 17:46","pubTimestamp":1720777616,"startTime":"0","endTime":"0","summary":"格隆汇7月12日丨药明合联(02268.HK)宣布，于2024年7月12日，根据2024年股份计划，其已批准向211名承授人授出4,496,948股受限制股份，其中三名承授人为董事，其余208名承授人为集团雇员，惟须经选定参与者接纳。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407121747389f3aebe3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407121747389f3aebe3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","SG9999014674.SGD","02268"],"gpt_icon":0},{"id":"2450043003","title":"药明合联(02268)授出449.69万股受限制股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2450043003","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450043003?lang=zh_cn&edition=full","pubTime":"2024-07-12 17:46","pubTimestamp":1720777595,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明合联(02268)发布公告，于2024年7月12日，根据2024年股份计划，其已批准向211名承授人授出449.69万股受限制股份，其中3名承授人为董事，其余208名承授人为集团雇员，惟须经选定参与者接纳。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1150116.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999014674.SGD","02268","BK1141"],"gpt_icon":0},{"id":"2450609960","title":"港股异动 | 药明合联(02268)现涨超5% ADC药物研发和对外授权交易活跃 公司商业化可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2450609960","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450609960?lang=zh_cn&edition=full","pubTime":"2024-07-09 15:48","pubTimestamp":1720511295,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，药明合联现涨超5%，截至发稿，涨4.22%，报15.8港元，成交额1751.52万港元。受益于ADC药物研发和对外授权交易活跃，公司总收入从2020年的0.96亿元增长至2023年的21.24亿元，2020-2023年复合增速为180%。此外，2023年公司调整后净利润为4.12亿元，同比增长112%。随着项目进入后期阶段，IND后服务收入贡献从2020年的45%增长至2023年的56%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1147622.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02268","BK1141","ADC","SG9999014674.SGD","07226","HSCEI","BK4080","HSTECH","BK4231","YANG"],"gpt_icon":0},{"id":"2450109957","title":"药明合联(02268)上涨5.01%，报15.92元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2450109957","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450109957?lang=zh_cn&edition=full","pubTime":"2024-07-09 15:39","pubTimestamp":1720510792,"startTime":"0","endTime":"0","summary":"7月9日，药明合联(02268)盘中上涨5.01%，截至15:39，报15.92元/股，成交1598.97万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2023年年报，药明合联营业总收入21.24亿元、净利润2.84亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/09153941454493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SG9999014674.SGD","BK1141","02268"],"gpt_icon":0},{"id":"2450099252","title":"药明合联(02268)股价上升5.013%，现价港币$15.92","url":"https://stock-news.laohu8.com/highlight/detail?id=2450099252","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450099252?lang=zh_cn&edition=full","pubTime":"2024-07-09 15:39","pubTimestamp":1720510740,"startTime":"0","endTime":"0","summary":"[上升股]药明合联(02268) 股价在下午03:39比前收市价上升5.013%，现股价为港币$15.92。至目前为止，今日最高价为$15.92，而最低价为$14.86。总成交量为103.95万股，总成交金额为港币$1.599千万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180725133914771_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180725133914771_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2407091626/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["SG9999014674.SGD","BK1141","02268"],"gpt_icon":0},{"id":"2450905564","title":"南向资金7月8日净买入药明合联6.65万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2450905564","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450905564?lang=zh_cn&edition=full","pubTime":"2024-07-09 09:31","pubTimestamp":1720488688,"startTime":"0","endTime":"0","summary":"7月8日, 南向资金增持药明合联6.65万股，连续3日增持。截止当日收盘，港股通共持有药明合联5787.55万股，占流通股4.82%。港股通增持金额前五个股分别为工商银行、中国石油化工股份、建设银行、理想汽车-W、紫金矿业。药明合联近5个交易日下跌12.37%，港股通累计增持50.05万股；近20个交易日下跌2.19%，港股通累计增持209.05万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407090943049593e5f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407090943049593e5f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","SG9999014674.SGD","02268"],"gpt_icon":0},{"id":"2449719379","title":"药明合联(02268)下跌5.34%，报14.9元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2449719379","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449719379?lang=zh_cn&edition=full","pubTime":"2024-07-08 10:36","pubTimestamp":1720406203,"startTime":"0","endTime":"0","summary":"7月8日，药明合联(02268)盘中下跌5.34%，截至10:36，报14.9元/股，成交702.87万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2023年年报，药明合联营业总收入21.24亿元、净利润2.84亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/08103641425875.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SG9999014674.SGD","BK1141","02268"],"gpt_icon":0},{"id":"2446785123","title":"药明合联(02268)下跌5.0%，报17.1元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446785123","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446785123?lang=zh_cn&edition=full","pubTime":"2024-06-27 10:32","pubTimestamp":1719455577,"startTime":"0","endTime":"0","summary":"6月27日，药明合联(02268)盘中下跌5.0%，截至10:32，报17.1元/股，成交735.47万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2023年年报，药明合联营业总收入21.24亿元、净利润2.84亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062710352095dc6b5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062710352095dc6b5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999014674.SGD","02268","BK1141"],"gpt_icon":0},{"id":"2445277576","title":"太平洋证券：药明合联(02268)业绩有望持续高增长 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2445277576","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445277576?lang=zh_cn&edition=full","pubTime":"2024-06-21 09:35","pubTimestamp":1718933707,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，太平洋证券发布研究报告称，维持药明合联“买入”评级，根据在手订单数量以及客户的管线进展分布，预测公司2024/2025/2026年的净利润分别为6.50/9.92/13.25亿。一直笼罩着药明系的生物安全法案的阴霾暂时减轻了一些，药明合联的业绩有望迎来持续高增长。现有项目及“赢得分子”项目推进到后期阶段，推动整体收入增加。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1138408.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601099","161027","02268"],"gpt_icon":0},{"id":"2444118440","title":"药明合联06月19日获主力加仓336万元 环比增加348.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2444118440","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444118440?lang=zh_cn&edition=full","pubTime":"2024-06-19 16:15","pubTimestamp":1718784906,"startTime":"0","endTime":"0","summary":"06月19日, 药明合联股价涨3.92%，报收17.50元，成交金额5444万元，换手率0.26%，振幅5.23%，量比0.77。药明合联今日主力资金净流入336万元，连续3日净流入，上一交易日主力净流入75万元，今日环比增加348.00%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为28.57%，平均涨幅为2.67%。该股近5个交易日上涨3.71%，主力资金累计净流出225万元；近20日主力资金累计净流入8万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061916152095c1141a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061916152095c1141a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999014674.SGD","BK1141","02268"],"gpt_icon":0},{"id":"2442555393","title":"智通港股解盘 | 生物安全法案暂停CXO迎反弹 关注晚间两重磅消息","url":"https://stock-news.laohu8.com/highlight/detail?id=2442555393","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442555393?lang=zh_cn&edition=full","pubTime":"2024-06-12 20:14","pubTimestamp":1718194458,"startTime":"0","endTime":"0","summary":"关于加沙停火一事出现变故，哈马斯积极回应加沙停火方案，布林肯称令人鼓舞，但媒体引述以色列官员报道，哈马斯修改了所有基本内容，变相拒绝了停火建议。知情人士称，欧盟将于周三通知汽车制造商，从下月起对进口自中国的电动汽车暂时征收最高达25%的额外关税。目前是临时关税，根据欧盟法规，接下来是各成员国、制造商的协商阶段，中欧之间也将开始一系列谈判，确定细则，直到11月初则正式生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1134374.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359201612.USD","SG9999002562.SGD","02269","LU0173614495.USD","LU0359202008.SGD","CXO","LU0417516902.SGD","LU0541502299.USD","LU2039709279.SGD","LU1794554557.SGD","BK1603","02268","LU0320764599.SGD","07226","LU0823426480.USD","LU0181495838.USD","LU0327786744.USD","YANG","BK1141","00564","SG9999001069.SGD","LU0541501648.USD","LU0516423174.USD","LU0823426308.USD","SG9999001051.SGD","BK1171","BK1543","SG9999002463.SGD","LU0856984785.SGD","00288","SGXZ90724238.SGD","HSCEI","SG9999014674.SGD","BK1610","BK1521","LU0516423091.SGD","LU0348735423.USD","BK1589","01610","BK1576","LU1880383366.USD","LU0051755006.USD","LU0052750758.USD","LU0417516738.SGD","LU0456827905.SGD","HSTECH","LU0979878070.USD","LU0043850808.USD","BK1549","LU0702159699.USD"],"gpt_icon":0},{"id":"2442929533","title":"《生物安全法案》危机暂时解除，CXO板块全线大涨，药明系集体走高丨钛媒体焦点","url":"https://stock-news.laohu8.com/highlight/detail?id=2442929533","media":"钛媒体","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442929533?lang=zh_cn&edition=full","pubTime":"2024-06-12 17:38","pubTimestamp":1718185091,"startTime":"0","endTime":"0","summary":"药明康德率先回应，此前还获摩根大通增持6月12日，在药明康德举办的2023年年度股东大会上，其管理层针对上述消息作出回应。公司了解到，关于将《生物安全法案》加入2025国防授权法案的修正案未能获得众议院规则委员会的批准，因此《生物安全法案》目前不会进入众议院的2025国防授权法案的立法议程，其后续立法路径仍有待明确。在这一消息发酵之际，港A两市CXO板块大幅拉升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406121738189f347f2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406121738189f347f2d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0043850808.USD","LU0456827905.SGD","LU0516423091.SGD","LU0516423174.USD","LU0039217434.USD","LU1720050803.USD","LU0320764599.SGD","BK1583","LU0327786744.USD","LU1794554557.SGD","LU0516422440.USD","SG9999002562.SGD","LU0456846285.SGD","LU0359201612.USD","LU0856984785.SGD","SG9999002463.SGD","BK1589","LU0181495838.USD","LU2039709279.SGD","LU0052750758.USD","BK1141","LU0979878070.USD","LU1688375341.USD","LU0307460666.USD","LU1242518857.USD","LU0348735423.USD","LU0051755006.USD","LU0359202008.SGD","LU0516422952.EUR","BK1576","LU0348825331.USD","02268","02359","BK1521","LU1880383366.USD","LU0326950275.SGD","LU0823426308.USD","LU0140636845.USD","LU0819121731.USD","02269","BK1610","JPM","LU0588546209.SGD","SG9999014674.SGD","LU0417516902.SGD","LU1242518931.SGD","LU0823426480.USD","LU0516422366.SGD","LU0708995583.HKD","603259","IE00B0JY6N72.USD","01548","LU0417516738.SGD"],"gpt_icon":0},{"id":"2442758374","title":"CRO概念早盘普涨 药明合联及药明生物均涨逾8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2442758374","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442758374?lang=zh_cn&edition=full","pubTime":"2024-06-12 10:48","pubTimestamp":1718160519,"startTime":"0","endTime":"0","summary":"CRO概念早盘普涨，药明合联（02268）上涨8.19%，报16.38港元；药明生物（02269）上涨7.83%，报11.84港元；药明康德（02359）上涨5.43%，报34.95港元；君实生物（01877）上涨4.60%，报12.74港元。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-06-12/doc-inaymwmi7605697.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-06-12/doc-inaymwmi7605697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["LU0823426308.USD","LU0417516738.SGD","LU0052750758.USD","LU0181495838.USD","LU1880383366.USD","LU1794554557.SGD","LU0708995583.HKD","BK1521","LU0456846285.SGD","LU0348825331.USD","BK1141","BK1610","02268","LU0043850808.USD","LU0140636845.USD","LU0516422366.SGD","LU0320764599.SGD","SG9999014674.SGD","LU0516423091.SGD","LU0051755006.USD","02269","LU0516423174.USD","BK1589","LU0327786744.USD","LU0856984785.SGD","LU1242518857.USD","LU0417516902.SGD","LU0516422952.EUR","LU1688375341.USD","IE00B0JY6N72.USD","LU0326950275.SGD","SG9999002562.SGD","LU0516422440.USD","LU0456827905.SGD","LU0823426480.USD","LU0307460666.USD","LU1242518931.SGD","LU0588546209.SGD","LU0572944931.SGD","LU1720050803.USD","LU0039217434.USD","LU0359201612.USD","LU0359202008.SGD","LU0348735423.USD","LU0979878070.USD","LU2039709279.SGD","SG9999002463.SGD","LU0819121731.USD","BK1576"],"gpt_icon":0},{"id":"2442819372","title":"生物制药板块逆市走高 药明合联(02268)涨超7% 机构料行业整体表现将逐步改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2442819372","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442819372?lang=zh_cn&edition=full","pubTime":"2024-06-12 10:43","pubTimestamp":1718160229,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物制药板块逆市走高，药明系领涨，药明合联 涨6.87%，药明生物涨5.28%，药明康德涨4.07%。进入2024年，一季度医药行业全板块的营收同比略微下降了0.21%，这表明基数效应和合规要求提升的影响仍在持续。但研报预计，从第二季度开始，随着高基数因素的影响逐步减弱，以及企业对合规新常态的适应，整体增速将逐步企稳。这表明，尽管医药行业在短期内面临一些挑战，但随着时间的推移和行业适应性的提高，预计行业的整体表现将逐步改善。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1938479","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0819121731.USD","LU0327786744.USD","BK1515","LU2039709279.SGD","LU0823426480.USD","01672","LU0516423091.SGD","01228","LU0359202008.SGD","LU2242644610.SGD","BK1574","BK1583","LU0572944931.SGD","SG9999002562.SGD","02269","LU0181495838.USD","LU0823426308.USD","LU0456827905.SGD","LU0456846285.SGD","LU0326950275.SGD","LU0516422952.EUR","LU1720050803.USD","LU0516423174.USD","BK1521","LU0417516738.SGD","02359","LU0348825331.USD","LU0051755006.USD","LU0140636845.USD","SG9999014674.SGD","LU1242518857.USD","LU0516422366.SGD","BK1589","LU1242518931.SGD","LU0043850808.USD","02268","BK1141","LU2045819591.USD","LU1794554557.SGD","LU0708995583.HKD","LU0979878070.USD","BK1161","IE00B0JY6N72.USD","LU0348735423.USD","BK1576","LU0052750758.USD","LU0516422440.USD","LU1880383366.USD","LU0417516902.SGD","LU0856984785.SGD"],"gpt_icon":0},{"id":"2442374603","title":"港股异动 | 药明合联(02268)涨超8%领涨CRO概念 下游需求端有待好转 板块整体估值处于低位","url":"https://stock-news.laohu8.com/highlight/detail?id=2442374603","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442374603?lang=zh_cn&edition=full","pubTime":"2024-06-12 10:41","pubTimestamp":1718160067,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，CRO概念早盘普涨，截至发稿，药明合联涨6.87%，报16.18港元；药明生物涨5.28%，报11.56港元；药明康德涨4.07%，报34.5港元；君实生物涨2.79%，报12.52港元。中信建投指出，目前医药领域一级投融资仍有待恢复，下游需求端有待好转。临床CRO领域匹配高端需求的公司有望获得更高份额。目前CXO板块整体估值处于低位，长期来看，我们仍旧看好CXO板块发展潜力及成长空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1133967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1720050803.USD","LU0456827905.SGD","SG9999002562.SGD","02269","LU0359202008.SGD","LU0819121731.USD","LU0417516902.SGD","LU2039709279.SGD","LU0516422366.SGD","LU1688375341.USD","LU1794554557.SGD","LU0516422440.USD","02268","LU0320764599.SGD","07226","LU1242518931.SGD","LU0823426480.USD","BK1515","LU0572944931.SGD","LU0181495838.USD","LU0327786744.USD","YANG","BK1141","BK1583","LU0516423174.USD","LU0823426308.USD","LU2242644610.SGD","LU0348825331.USD","02359","LU0856984785.SGD","HSCEI","SG9999014674.SGD","BK1161","BK1610","LU0456846285.SGD","LU0516423091.SGD","LU0348735423.USD","BK1589","LU0708995583.HKD","BK1576","LU1880383366.USD","LU0140636845.USD","LU1046422090.SGD","LU2125910500.SGD","IE00B0JY6N72.USD","LU1242518857.USD","LU0417516738.SGD","01877","HSTECH","LU0043850808.USD"],"gpt_icon":0},{"id":"2442740653","title":"药明合联(02268)股价上升5.02%，现价港币$15.9","url":"https://stock-news.laohu8.com/highlight/detail?id=2442740653","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442740653?lang=zh_cn&edition=full","pubTime":"2024-06-12 10:34","pubTimestamp":1718159640,"startTime":"0","endTime":"0","summary":"[上升股]药明合联(02268) 股价在上午10:34比前收市价上升5.02%，现股价为港币$15.9。至目前为止，今日最高价为$15.9，而最低价为$15.2。总成交量为126.75万股，总成交金额为港币$1.961千万。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2406121091/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["SG9999014674.SGD","02268","BK1141"],"gpt_icon":0}],"profile":{"websiteUrl":"http://wuxixdc.com","stockEarnings":[{"period":"1week","weight":-0.0532},{"period":"1month","weight":-0.2124},{"period":"3month","weight":-0.288},{"period":"6month","weight":-0.4349},{"period":"1year","weight":-0.3087},{"period":"ytd","weight":-0.555}],"compareEarnings":[{"period":"1week","weight":-0.0241},{"period":"1month","weight":-0.0398},{"period":"3month","weight":0.0015},{"period":"6month","weight":0.0852},{"period":"1year","weight":-0.1093},{"period":"ytd","weight":0.0155}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"WuXi XDC Cayman Inc是一家主要从事提供抗体偶联药物（ADC）及更广泛生物偶联药物的合同研究、开发和生产服务（CRDMO）的控股公司。该公司通过两个分部开展其业务。按有偿服务基准的研究服务分部透过有偿服务合约向客户提供研究服务。按全时当量基准提供的研究服务分部提供一个项目小组，该小组的员工在特定时间内专门负责客户的研究。基于生物药和小分子药物，该公司还提供跨领域的综合服务，涵盖生物偶联药物及连接子及有效载荷的发现、工艺开发及药品生产质量管理规范（GMP）生产。该公司在国内外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.222222,"avgChangeRate":0.010265},{"month":2,"riseRate":0.666667,"avgChangeRate":0.058284},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.010372},{"month":4,"riseRate":0.555556,"avgChangeRate":0.03555},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006014},{"month":6,"riseRate":0.4,"avgChangeRate":-0.032735},{"month":7,"riseRate":0.4,"avgChangeRate":0.011785},{"month":8,"riseRate":0.4,"avgChangeRate":-0.114063},{"month":9,"riseRate":0.333333,"avgChangeRate":0.019767},{"month":10,"riseRate":0.777778,"avgChangeRate":0.151657},{"month":11,"riseRate":0.333333,"avgChangeRate":0.008796},{"month":12,"riseRate":0.111111,"avgChangeRate":-0.068876}],"exchange":"SEHK","name":"药明合联","nameEN":"WUXI XDC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明合联,02268,药明合联股票,药明合联股票老虎,药明合联股票老虎国际,药明合联行情,药明合联股票行情,药明合联股价,药明合联股市,药明合联股票价格,药明合联股票交易,药明合联股票购买,药明合联股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}